Teva Pharma has posted a net income of $800m for the second quarter 2010, or $ 0.88 per diluted share, compared to $523m or $0.58 per diluted share for the comparable period in 2009. Operating income was $1bn compared to $702m for the comparable period in 2009.
For the six months ended June 30, 2010, the company has posted a net income of $1.5bn, or $1.66 per diluted share compared to $974m, or $1.09 per diluted share for the year ago period.
Shlomo Yanai, president and CEO of Teva Pharma, said: “It was an especially strong quarter in North America, where we had nine new product launches, and in Europe, where we experienced growth.”